Results 101 to 110 of about 4,636,278 (309)

Contribution of adverse events to death of hospitalised patients [PDF]

open access: yes, 2019
Background - There is no standardised method to investigate death as a patient safety indicator and we need valid and reliable measurements to use adverse events contributing to death as a quality measure.
Nieder, Carsten   +9 more
core   +1 more source

Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysis

open access: yesBMC Medicine
Background Immune checkpoint inhibitors (ICIs) have transformed tumor treatment. However, the risk of pulmonary adverse events (PAEs) associated with ICI combination therapy is still unclear.
Baohui Hong   +6 more
doaj   +1 more source

Target-specific cardiotoxicity of tyrosine kinase inhibitors: a Systematic Review and meta-analysis

open access: yesFrontiers in Pharmacology
ObjectiveTo assess the association between different tyrosine kinase inhibitors (TKIs) and the risk of major adverse cardiovascular events (MACE).Data sourcesPubMed, the Cochrane Library, Embase, WanFang Data, and CNKI were searched for randomized ...
Zhe Wang   +10 more
doaj   +1 more source

GelMA‐based 3D spheroids recapitulate transcriptomic and functional hallmarks of myeloid sarcoma

open access: yesFEBS Open Bio, EarlyView.
GelMA 5% hydrogels support the formation of myeloid leukemia spheroids that recapitulate MS‐specific features, including G1 arrest, apoptosis, and ECM‐driven transcriptomic reprogramming. The 3D model mimicked soft‐tissue‐like stiffness and oxygen conditions, and transcriptomic convergence with primary MS samples confirmed its utility as a preclinical ...
Nicolas Germain   +11 more
wiley   +1 more source

TRPML1 agonist ML‐SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux

open access: yesFEBS Open Bio, EarlyView.
TGF‐β1 stimulation downregulates lysosomal channel TRPML1 in pulmonary fibroblasts. The TRPML1 agonist ML‐SA5 suppressed fibroblast‐to‐myofibroblast activation and collagen production. Mechanistically, ML‐SA5 inhibited mTOR phosphorylation, restored autophagic flux, and its effects were enhanced by rapamycin (mTOR inhibitor) and reversed by MHY1485 ...
Jiatong Yao   +10 more
wiley   +1 more source

An Estimate of the proportion of symptoms reported in Self-administered questionnaires that are captured as adverse drug events in an observational database [PDF]

open access: yes, 2007
Purpose: This study was conducted to determine how frequently self-reported symptoms are captured as adverse drug events (ADEs) during chart abstraction.
Walmsley, S.   +5 more
core  

Evaluation of Adverse Events during Plateletpheresis – A Retrospective Study

open access: yesIndian Journal of Medical Specialities
Introduction: Apheresis is a routine procedure which is well tolerated but may be associated with different adverse events (AEs). In this study, the frequency of various AEs associated with apheresis was evaluated, and the donor variables were analyzed ...
Shivali Sehgal   +5 more
doaj   +1 more source

Five‐Year Outcomes of Laparoscopic Sphincter‐Preserving Surgery for Rectal Cancer: A Prospective Study in Elderly Vietnamese Patients

open access: yesAging and Cancer, EarlyView.
This prospective study demonstrates that laparoscopic sphincter‐preserving surgery is feasible for elderly patients. While overall survival reaches 70% at 5 years, advanced T‐stage and the omission of neoadjuvant therapy significantly drive recurrence, highlighting the need for personalized geriatric protocols despite logistical challenges.
Huu Duc Ho   +4 more
wiley   +1 more source

Personal Bankruptcy: Reconciling Adverse Events and Strategic Timing Hypotheses Using Heterogeneity in Filing Types [PDF]

open access: yes
The strategic timing and adverse events hypotheses of personal bankruptcy have received particular attention. Existing research focuses on proving or disproving either hypothesis, using a strict interpretation of the role of financial benefit in the ...
Tarun Sabarwal, Shuoxun Zhang, Li Gan
core  

Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials [PDF]

open access: yes, 2011
Giuseppe Mancia1, Helmut Schumacher21Universita degli Studi Milano-Bicocca, Ospedale San Gerardo di Monza, Milan, Italy; 2Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, GermanyAbstract: Telmisartan is indicated for the prevention of ...
Schumacher H, Mancia G
core  

Home - About - Disclaimer - Privacy